News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bavarian Nordic (BAVA.CO)'s MVA-BN® Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development



2/21/2014 8:43:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KVISTGAARD, Denmark, February 21, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security - Burkholderia pseudomallei and Burkholderia mallei.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES